Update on NVA237 and QVA149 for Chronic Obstructive Pulmonary Disease
QVA149 is a novel once-daily, dry powder, fixed dose, bronchodilator combination of the once-daily beta2-agonist indacaterol and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide), in development for the treatment of chronic obstructive pulmonary disease (COPD). Novartis announced on
Mr Shinichi Tamura, President and CEO of Sosei said: "Progress with Phase III studies evaluating NVA237, and the rapid review and recommendation for approval of indacaterol in
Notes for Editors:
About the NVA237 Licence Agreement with Novartis
NVA237 was licensed to Novartis in
NVA237 entered Phase III trials in
About COPD
COPD is a chronic obstruction of the airways which affects 210 million people worldwide and is projected to be the third leading cause of death by 2030. Commonly caused by cigarette smoke and other harmful fumes COPD is a progressive lung disease with symptoms including chronic bronchitis and/or emphysema, which slowly progresses and eventually leads to a largely irreversible loss of lung function. While there is no cure, bronchodilators such as LABAs and LAMAs make breathing easier by enlarging the patient's airways, and are recognised in international guidelines as an integral part of the treatment for COPD.
About Sosei
Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into,
Forward-Looking Statements
This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: Enquiries: Sosei Group Corporation, Kojimachi Tsuruya Hachiman Bldg., 5F, 2-4 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Japan, Hidetoshi Torami, Tel +81-3-5210-3399, Fax +81-3-5210-3291, E-mail: [email protected]; 1F London BioScience Innovation Centre, 2 Royal College Street, London, NW1 0NH, Yumi Yamamoto-Tyrrell, Manager, Finance and IR Europe, Tel +44-20-7691-2081, Fax +44-20-7209-2484, E-mail: [email protected]
Share this article